Péptidos y Proteínas
Los péptidos son cadenas cortas de aminoácidos unidas por enlaces peptídicos, mientras que las proteínas son cadenas más largas y complejas de aminoácidos que pueden adoptar estructuras tridimensionales funcionales. Ambos tipos de compuestos son esenciales para diversas funciones biológicas, como la catalización de reacciones (enzimas), la defensa inmunológica (anticuerpos) y la señalización celular. Las proteínas tienen una estructura jerárquica, que incluye la secuencia de aminoácidos, la estructura secundaria, terciaria y cuaternaria. Los péptidos se utilizan en terapias farmacológicas y cosméticas por sus propiedades biológicas específicas, como en el tratamiento de enfermedades metabólicas o la mejora de la regeneración celular. Las proteínas, por su parte, tienen aplicaciones en biotecnología, nutrición y medicina regenerativa.
En CymitQuimica ofrecemos péptidos y proteínas de alta pureza para investigación en biotecnología y aplicaciones terapéuticas.
Se han encontrado 3117 productos de "Péptidos y Proteínas"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
N-[(1S)-2-[(3-Methylbutyl)amino]-2-oxo-1-(phenylmethyl)ethyl]-2-pyrazinecarboxamide
CAS:Producto controladoFórmula:C19H24N4O2Forma y color:White To Off-WhitePeso molecular:340.41951-Nitrosopyrrolidine-2-carboxylic Acid
CAS:Producto controlado<p>Applications 1-nitrosopyrrolidine-2-carboxylic acid (cas# 2571-28-0) is a useful research chemical.<br></p>Fórmula:C5H8N2O3Forma y color:NeatPeso molecular:144.129(R)-Lisinopril Sodium Salt
CAS:<p>Applications R,S,S-Isomer of Lisinopril (L468985).<br>References Goa, K.L., et al.: Drugs, 52, 564 (1996), Chaturvedi, N., et al.: Lancet, 351, 28 (1998)<br></p>Fórmula:C21H31N3NaO5Forma y color:NeatPeso molecular:428.48rhPTH (1-30) Trifluoroacetic Acid Salt Hydrate
Producto controlado<p>Impurity Teriparatide Impurity<br>Applications A fragment of human parathyroid hormone (hPTH) peptide sequence containing the 30 N-terminal residues of hPTH.<br>References Niall, et al.: Proc. Natl. Acad. Sci., 71, 384 (1974);<br></p>Fórmula:C157H260N48O46S2•x(C2HF3O2)•y(H2O)Forma y color:NeatPeso molecular:3620.171140218Sacubitril Calcium
CAS:<p>Applications Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug, valsartan/sacubitril, known during trials as LCZ696 and marketed under the brand name, Entresto, is a treatment for heart failure.<br>References McMurray, J., et al.: N. Eng. J. Med., 371 (2014)<br></p>Fórmula:C24H28NOCa2Forma y color:NeatPeso molecular:430.52Carfilzomib (2S,4R)-Diol
Producto controlado<p>Applications Carfilzomib (2S,4R)-Diol is a derivative of Carflizomib (C183460), a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.<br>References Fostier, K., et al.: Oncotargets. Therap., 5, 237 (2012); Geurink, P.P., et al.: J. Med. Chem., 56, 1262 (2013); McCormack, P.L., et al.: Drugs., 72, 2023 (2012);<br></p>Fórmula:C40H59N5O8Forma y color:NeatPeso molecular:737.93L-Methionine-34S
CAS:<p>Applications Labelled L-Methionine, an essential aminoacid for human development. Hepatoprotectant; antidote (acetominophen poisoning); urinary acidifier.<br>References Benevenga, N.J., et al.: J. Agric. Food Chem., 22, 2 (1974), Fleisher, L.D., et al.: Clin. Endocrinol. Metab., 3, 37 (1974), Meinnel, T., et al.: Biochimie, 75, 1061 (1993),<br></p>Fórmula:C5H11NO234SForma y color:NeatPeso molecular:151.11(S)-Tetrahydro-α-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetic Acid
CAS:Producto controladoFórmula:C9H16N2O3Forma y color:NeatPeso molecular:200.23D-Val(10)-Semaglutide
<p>D-Val(10)-Semaglutide is a semaglutide impurity. The amino acid at position 10 has been replaced by the D-form of the amino acid D-valine (D-Val). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molD-Ala(24)-Semaglutide
<p>D-Ala(24)-Semaglutide is a semaglutide impurity. The amino acid at position 24 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molSemaglutide Impurity 59
<p>D-Arg(28)-Semaglutide is a semaglutide impurity. The amino acid at position 28 has been replaced by the D-form of the amino acid D-arginine (D-Arg). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molD-His(1)-Semaglutide
<p>D-His(1)-Semaglutide is a semaglutide impurity. The amino acid at position 1 has been replaced by the D-form of the amino acid D-histidine (D-His). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/mol(S,E)-N-(1-(3-Methylbut-1-enylamino)-1-oxo-3-phenylpropan-2-yl)pyrazine-2-carboxamide
CAS:<p>R-N-(1-(3-methylbut-1-enyl)-1-oxo-3-phenylpropan-2-yl) pyrazine-2-carboxamide is a drug product that is used for the treatment of bacterial infections. The compound is an impurity in the synthesis of other compounds and is also used as an analytical standard. It is synthesized from commercially available starting materials and through custom synthesis. R-N-(1-(3-methylbut-1-enyl)-1--oxo--3--phenylpropan--2--yl)pyrazine--2--carboxamide has been shown to be metabolized by CYP450 enzymes, which are responsible for the metabolism of many drugs. R-(1-(3Methylbut 1Enylamino)-1Oxo 3Phenylpropan 2Yl)Pyrazine 2Carboxamide has not been evaluated as a drug product and therefore does not</p>Fórmula:C19H22N4O2Pureza:Min. 95%Peso molecular:338.4 g/molBortezomib intermediate I
CAS:<p>Bortezomib intermediate I is a metabolite of bortezomib, which is a research and development drug product. Bortezomib intermediate I is an impurity standard for bortezomib. Bortezomib intermediate I can be synthesized from the corresponding compound. It is an analytical standard used in pharmacopoeia and can be used as an API impurity or synthetic material in drug development. Bortezomib intermediate I has a high purity, natural origin, and a niche application. CAS No. 1248339-44-7</p>Fórmula:C25H36BN5O4Pureza:Min. 95%Forma y color:White PowderPeso molecular:481.4 g/molSemaglutide Impurity 60 (D-Arg 30)
<p>D-Arg(30)-Semaglutide is a semaglutide impurity. The amino acid at position 30 has been replaced by the D-form of the amino acid D-arginine (D-Arg). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molDes-His(1)-Semaglutide
<p>Des-His(1)-semaglutide is a semaglutide-related impurity. This des-amino acid form has the histidine (His) amino acid from position 1 removed from the peptide chain. Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist used for managing type 2 diabetes and obesity.</p>Fórmula:C181H284N42O58Peso molecular:3,976.5 g/molDes-Glu(3)-Semaglutide
<p>Des-Glu(3)-semaglutide is a semaglutide-related impurity. This des-amino acid form has got the glutamic acid or glutamate (Glu) amino acid from position 3 removed from the peptide chain. Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist used for managing type 2 diabetes and obesity.</p>Fórmula:C182H284N44O56Peso molecular:3,984.53 g/molD-Asp(9)-Semaglutide
<p>D-Asp(9)-Semaglutide is a semaglutide impurity. The amino acid at position 9 has been replaced by the D-form of the amino acid D-aspartic acid (D-Asp). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molD-Ser-(12)-Semaglutide
<p>D-Ser(12)-Semaglutide is a semaglutide impurity. The amino acid at position 12 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molSemaglutide Impurity 29 (β-Asp-9)
<p>Beta-Asp-(9)-Semaglutide is a semaglutide impurity. The amino acid at position 9 has been replaced by the beta-aspartic acid (also known as isoaspartic, isoAsp, β-Asp or beta-Asp). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molSemaglutide Impurity 51 (D-Thr 7)
<p>D-Thr(7)-Semaglutide is a semaglutide impurity. The amino acid at position 7 has been replaced by the D-form of the amino acid D-threonine (D-Thr). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molLinear Semaglutide
<p>Linear semaglutide, or simply L-Sema, is the semaglutide compound without the lipid side chain modification. It is essentially a linear version of the peptide.</p>Fórmula:C152H230N42O47Peso molecular:3,397.76 g/molD-Ser(11)-Semaglutide
<p>D-Ser(11)-Semaglutide is a semaglutide impurity. The amino acid at position 11 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molD-Ala-(19)-Semaglutide
<p>D-Ala(19)-Semaglutide is a semaglutide impurity. The amino acid at position 19 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molSemaglutide Impurity 56 (D-Glu 21)
<p>D-Glu(21)-Semaglutide is a semaglutide impurity. The amino acid at position 21 has been replaced by the D-form of the amino acid D-glutamic acid (D-Glu). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molLisinopril EP Impurity E
CAS:<p>Lisinopril EP Impurity E is an impurity of lisinopril, which is a prescription drug used to treat high blood pressure. This impurity was found in a preparative high performance liquid chromatography (HPLC) and mass spectroscopy analysis of the drug. The molecular weight of Lisinopril EP Impurity E was determined to be 317.2 amu, which corresponds to the molecular formula C7H13NO2. The FT-IR spectrum showed that this impurity has an ammonium group at 1859 cm-1 and butanoic acid at 1647 cm-1.</p>Fórmula:C21H31N3O5Pureza:Min. 98 Area-%Forma y color:PowderPeso molecular:405.49 g/molSemaglutide Impurity 54 (D-Ala 18)
<p>D-Ala(18)-Semaglutide is a semaglutide impurity. The amino acid at position 18 has been replaced by the D-form of the amino acid D-alanine (D-Ala). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molD-Ser(8)-Semaglutide
<p>D-Ser(8)-Semaglutide is a semaglutide impurity. The amino acid at position 8 has been replaced by the D-form of the amino acid D-serine (D-Ser). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molSemaglutide Impurity 101 (D-Glu 3)
<p>D-Glu(3)-Semaglutide is a semaglutide impurity. The amino acid at position 3 has been replaced by the D-form of the amino acid D-glutamic acid (D-Glu). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molD-Thr(5)-Semaglutide
<p>D-Thr(5)-Semaglutide is a semaglutide impurity. The amino acid at position 5 has been replaced by the D-form of the amino acid D-threonine (D-Thr). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/molD-Phe(6)-Semaglutide
<p>D-Phe(6)-Semaglutide is a semaglutide impurity. The amino acid at position 6 has been replaced by the D-form of the amino acid D-phenylalanine (D-Phe). Semaglutide impurities are structurally related compounds that arise during synthesis, purification, or storage of semaglutide, a long-acting GLP-1 receptor agonist for managing type 2 diabetes and obesity.</p>Fórmula:C187H291N45O59Peso molecular:4,113.64 g/mol(R)-3-Methyl-1-(pyrazine- 2-carboxamido)butylboronic acid
<p>The compound is a drug product, analytical, and research material. The molecule has been synthesized and purified by the company's chemists. It is not an API impurity but an impurity standard for HPLC. This compound is a synthetic chemical that does not occur naturally in any living organism. It has been developed for use in drug development and research. The compound was custom synthesized by the company's chemists to meet customer demand for high purity standards of this compound. It is used as a pharmacopoeia standard for HPLC analysis and drug development.</p>Pureza:Min. 95%3,3',5,5'-Tetraiodothyroformic acid
CAS:<p>Cymit Quimicaetic beta-D-glucosiduronic acid</p>Fórmula:C13H6I4O4Pureza:Min. 95 Area-%Forma y color:Off-White PowderPeso molecular:733.8 g/molLisinopril
CAS:<p>Lisinopril, an ACE inhibitor, treats hypertension, heart failure, heart attacks, and prevents diabetes-related eye and kidney issues.</p>Fórmula:C21H31N3O5Pureza:97.59% - 99.34%Forma y color:SolidPeso molecular:405.49(1S,2S)-Bortezomib
CAS:Producto controlado<p>Impurity Bortezomib USP Impurity G<br>Stability Hygroscopic<br>Applications (1S,2S)-Bortezomib is an isomer of Bortezomib (B675700), proteasome inhibitor. (1S,2S)-Bortezomib has been seen to inhibit serine proteases shown to lower cellular Aβ concentrations, associated with Alzheimer’s or hypertension.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Hardy, J. et al.: Science, 297, 353 (2002); Paris, D. et al.: Mol. Med. 17, 149 (2011);<br></p>Fórmula:C19H25BN4O4Forma y color:NeatPeso molecular:384.24(S)-(-)-α-Methylbenzylamine
CAS:Producto controlado<p>Applications (S)-(-)-α-Methylbenzylamine (cas# 2627-86-3) is a compound useful in organic synthesis.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br></p>Fórmula:C8H11NForma y color:NeatPeso molecular:121.18(2,6-Dimethylphenoxy)acetic Acid
CAS:Producto controladoFórmula:C10H12O3Forma y color:NeatPeso molecular:180.204-(Phenylamino)-1-benzyl-4-piperidinecarboxamide
CAS:Producto controlado<p>Applications Used as modulators of muscarinic receptors for treatment of CNS disorders.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Coghlan, M., et al.: J. Med. Chem., 44, 1627 (2001), Ashcroft, F., et al.: J. Clin. Invest., 115, 2047 (2005), Bryan, J., et al.: Curr. Pharm. Des., 11, 2699 (2005),<br></p>Fórmula:C19H23N3OForma y color:NeatPeso molecular:309.41Semaglutide impurity
CAS:<p>Lipid chain (stearic bi-acid) plus γ-glutamic acid or glutamate (γ-Glu) amino acid.</p>Fórmula:C35H63N3O13Peso molecular:733.89 g/molAlamethicin
CAS:<p>Alamethicin is isolated from Trichoderma viride. It is a channel-forming peptide antibiotic and induces voltage-gated conductance in model and cell membranes.</p>Fórmula:C92H150N22O25Pureza:98%Forma y color:SolidPeso molecular:1964.31CP5V
CAS:<p>CP5V, a PROTAC, degrades Cdc20, halts mitosis, and inhibits cancer growth by targeting it for VHL-mediated ubiquitination and proteasome destruction.</p>Fórmula:C46H66Cl3N9O12SPureza:98%Forma y color:SolidPeso molecular:1075.49Boceprevir-d9
CAS:Producto controlado<p>Applications A labelled NS3 serine protease inhibitor of hepatitis C virus. It is a COVID19-related research product.<br>References Malcolm, B., et al.: Antimicrob. Agents Chemother., 50, 1013 (2006); Cubero, M., et al.: Virology, 370, 237 (2008); Venkatraman, S., et al.: J. Med. Chem., 49, 6074 (2006);<br></p>Fórmula:C272H9H36N5O5Forma y color:NeatPeso molecular:528.73(2S)-1-Nitrosopyrrolidine-2-carboxamide
CAS:Producto controladoFórmula:C5H9N3O2Forma y color:NeatPeso molecular:143.14Voclosporin M1 (IM1-Diol-1) metabolite
Fórmula:C63H113N11O14Pureza:>85%Forma y color:NeatPeso molecular:1248.66Deschloro-4’-chloro Clomiphene Hydrochloride
CAS:Producto controlado<p>Applications An impurity of Clomiphene (C587025).<br></p>Fórmula:C26H29Cl2NOForma y color:NeatPeso molecular:442.42(S)-Hydroperoxy Des(boric Acid) Bortezomib
CAS:Producto controlado<p>Applications (S,S)-Hydroperoxy Des(boric Acid) Bortezomib is an impurity of Bortezomib (B675700), the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer.<br>References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005); Drahl C.: Chem. and Eng. News, 87, 41 (2009);<br></p>Fórmula:C19H24N4O4Forma y color:NeatPeso molecular:372.42(D-His2)-Leuprolide Trifluoroacetic Acid Salt
CAS:Producto controlado<p>Impurity Leuprolide Acetate EP Impurity B TFA salt<br>Applications Synthetic nonapeptide agonist analog of LH-RH. Antineoplastic (hormonal).<br>References Vilchez-Martinez, J.A., et al.: Biochem. Biophys. Res. Commun., 59, 1226 (1974), Sennello, L.T., et al.: J. Pharm. Sci., et al.: 75, 158 (1986), Wheeler, J.M., et al.: Am.J. Obstet. Gynecol., 167, 1367 (1992), Eri, L.M., et al.: J. Urol., 150, 359 (1993),<br></p>Fórmula:C59H84N16O12·x(C2HF3O2)Forma y color:NeatPeso molecular:1209.398(S)-Hydroxy Des(boric Acid) Bortezomib
CAS:Producto controlado<p>Impurity Bortezomib USP Impurity J<br>Applications (S)-Hydroxy Des(boric Acid) Bortezomib is an impurity in the synthesis of Bortezomib (B675700), the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.<br>References Nawrocki, S.T., et al: Cancer Research, 65, 11510 (2005); Drahl, C. et al.: Chem. and Eng. News, 87, 41 (2009)<br></p>Fórmula:C19H24N4O3Forma y color:NeatPeso molecular:356.42N-Nitroso-D,L-proline-d3
CAS:Producto controlado<p>Applications A labelled nitrosoamino acid with oncogenic activity.<br>References Nagasawa, H.T., et al.: J. Med. Chem., 16, 583 (1973)<br></p>Fórmula:C52H3H5N2O3Forma y color:Off-WhitePeso molecular:147.147
![N-[(1S)-2-[(3-Methylbutyl)amino]-2-oxo-1-(phenylmethyl)ethyl]-2-pyrazinecarboxamide](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTR%2Fthumb-webp%2FM291300.webp&w=3840&q=75)
